C12Y 304/21106
Hepsin
Official title: Hepsin (3.4.21.106)
C12Y304/21106 (Hepsin) appears on 0 US grants and 6 published applications in this corpus.
Search patents in C12Y- Granted patents
- 0
- Published applications
- 6
- Assignees
- 3
- Inventors
- 11
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
No granted patents in this class yet.
- Vh-vl interdomain angle based antibody humanization6 Aug 2026US 2026/0226163 A1Hoffmann-La Roche Inc.
- Nanoparticle for specifically hydrolyzing template protein molecule, and preparation and application thereof7 Jul 2022US 2022/0211867 A1Guangzhou University of Chinese Medicine (Guangzhou Institute of Traditional Chinese Medicine)
- Vh-vl interdomain angle based antibody humanization3 Dec 2020US 2020/0377590 A1Hoffmann-La Roche Inc.
- Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment25 Oct 2018US 2018/0305702 A1Advaxis, Inc.
- Vh-vl-interdomain angle based antibody humanization20 Jul 2017US 2017/0204182 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.